Security key
29286M113
enGene Therapeutics Inc. - *W EXP 10/31/202 (ENGNW)
CUSIP: 29286M113
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / *W EXP 10/31/202
- Total 13F shares
- 4,763,349
- Total 13F value
- $2,912,652
- Share change
- +1,084
- SEC-reported price per share
- $0.60
- Number of holders
- 14
- Value change
- -$3,216
- Number of buys
- 3
- Number of sells
- 2
Report period
Q1 2025
Institutions
14
Top holders
10
ENGNW full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2025
Previous quarter: Q4 2024
enGene Therapeutics Inc. SEC filings
enGene Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29286M113
Recent filing periods:
Ownership snapshot
Top reported holders of ENGNW - enGene Therapeutics Inc. - *W EXP 10/31/202 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Fonds de solidarite des t...
Disclosed value leader
Fonds de solidarite des t...
Comparable rows
15/15
Latest evidence
27 Jan 2025
3/4/5
13D/G
13F
Lead comparable stake: 4.5%
13D/G row: Fonds de solidarite des travailleurs et des travailleuses du Quebec
Showing 1-6 of 15 holder rows.
Quick read
Fonds de solidarite des travailleurs et des travailleuses du Quebec leads the comparable SEC ownership view at 4.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Fonds de solidarite des travailleurs et des travailleuses du Quebec's linked filing trail.
Comparable ownership
Top 5
Fonds de solidarite des travaille...
4.5%
Adage Capital Management, L.P.
3%
BIOTECHNOLOGY VALUE FUND L P
1.8%
Venrock Adviser, LLC
7.5%
Kynam Capital Management, LP
7.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Fonds de solidarite des travailleurs et des travailleuses du Quebec |
3/4/5
13D/G
10%+ Owner
|
4.5%
from 13D/G
|
$45,542,295
3,036,153 shares
|
— | 18 Apr 2024 |
| Adage Capital Management, L.P. |
13D/G
|
3%
|
$6,115,072
1,528,768 shares
|
$0 | 31 Dec 2024 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
1.8%
|
$3,781,608
945,402 shares
|
-$8,424,148 | 27 Jan 2025 |
| Venrock Adviser, LLC |
13F
Company
|
7.5%
|
$33,558,653
5,046,414 shares
|
— | 31 Dec 2024 |
| Kynam Capital Management, LP |
13F
Company
|
7.5%
|
$33,210,699
4,994,090 shares
|
— | 31 Dec 2024 |
| Deep Track Capital, LP |
13F
Company
|
6.8%
|
$30,307,874
4,557,575 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
14
Shares
4,763,349
Rows available
14
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
15
Q1 2025 holders
14
Holder diff
-1
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend